Login to Your Account

Clinic Roundup

Friday, December 9, 2011
• ChemoCentryx Inc., of Mountain View, Calif., began a Phase II trial of CCX140 for diabetic kidney disease. A previous Phase II trial showed safety and tolerability in Type II diabetics on stable doses of metformin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription